Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Inventiva S.A. IVA
$2.73
+$0.14 (5.00%)
На 18:02, 12 мая 2023
+1 218.68%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
115447708.00000000
-
week52high
11.75
-
week52low
2.22
-
Revenue
12179000
-
P/E TTM
-2
-
Beta
1.22137400
-
EPS
-1.52000000
-
Last Dividend
0.00000000
-
Next Earnings Date
29 мар 2023 г. в 04:00
Описание компании
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 22 дек 2021 г. |
| Roth Capital | Buy | Buy | 05 авг 2020 г. |
| Stifel | Buy | Buy | 04 авг 2020 г. |
| Guggenheim | Buy | Buy | 04 авг 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 23 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Inventiva S.A. (IVA) Q2 2022 Earnings Call Transcript
Seeking Alpha
22 сент 2022 г. в 16:36
Inventiva S.A. (NASDAQ:IVA ) Q2 2022 Earnings Conference Call September 22, 2022 8:00 AM ET Company Participants Frédéric Cren - Co-Founder and CEO Pierre Broqua - Co-Founder and CSO Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial Officer Philip Duong - Head, Investment Conference Call Participants Ed Arce - H.C.
Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks
Zacks Investment Research
08 сент 2022 г. в 11:17
Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
GlobeNewsWire
16 июн 2022 г. в 16:00
Daix (France), Long Island City (New York, United States), June 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, announced today that it will host a webcast event focused on NASH with the participation of three Key Opinion Leaders (KOLs) on June 28, 2022, following the EASL International Liver Congress™ 2022.
Here's Why Inventiva S.A. Sponsored ADR (IVA) Could be Great Choice for a Bottom Fisher
Zacks Investment Research
15 июн 2022 г. в 11:34
Inventiva S.A. Sponsored ADR (IVA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.